These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

340 related articles for article (PubMed ID: 26232492)

  • 1. Why has active immunotherapy not worked in lung cancer?
    Thomas A; Giaccone G
    Ann Oncol; 2015 Nov; 26(11):2213-20. PubMed ID: 26232492
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunotherapy for non-small-cell lung cancer.
    Thomas A; Jakopovic M
    Expert Opin Biol Ther; 2014 Aug; 14(8):1061-4. PubMed ID: 24878420
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunotherapeutic agents in non-small-cell lung cancer finally coming to the front lines.
    Ruiz R; Hunis B; Raez LE
    Curr Oncol Rep; 2014 Sep; 16(9):400. PubMed ID: 25030654
    [TBL] [Abstract][Full Text] [Related]  

  • 4. What future opportunities may immuno-oncology provide for improving the treatment of patients with lung cancer?
    Reck M
    Ann Oncol; 2012 Sep; 23 Suppl 8():viii28-34. PubMed ID: 22918925
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tecemotide: an antigen-specific cancer immunotherapy.
    Wurz GT; Kao CJ; Wolf M; DeGregorio MW
    Hum Vaccin Immunother; 2014; 10(11):3383-93. PubMed ID: 25483673
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vaccines in non-small cell lung cancer: rationale, combination strategies and update on clinical trials.
    De Pas T; Giovannini M; Rescigno M; Catania C; Toffalorio F; Spitaleri G; Delmonte A; Barberis M; Spaggiari L; Solli P; Veronesi G; De Braud F
    Crit Rev Oncol Hematol; 2012 Sep; 83(3):432-43. PubMed ID: 22366114
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Active immunotherapy for non-small-cell lung cancer: moving toward a reality.
    Perez CA; Santos ES; Raez LE
    Expert Rev Anticancer Ther; 2011 Oct; 11(10):1599-605. PubMed ID: 21999133
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of immunotherapy in stage III nonsmall cell lung cancer.
    Wrona A
    Curr Opin Oncol; 2019 Jan; 31(1):18-23. PubMed ID: 30489337
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Detection of tumor antigens and tumor-antigen specific T cells in NSCLC patients: Correlation of the quality of T cell responses with NSCLC subtype.
    Palata O; Podzimkova Hradilova N; Mysiková D; Kutna B; Mrazkova H; Lischke R; Spisek R; Adkins I
    Immunol Lett; 2020 Mar; 219():46-53. PubMed ID: 31931024
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vaccination therapy for non-small-cell lung cancer: review of agents in phase III development.
    Decoster L; Wauters I; Vansteenkiste JF
    Ann Oncol; 2012 Jun; 23(6):1387-93. PubMed ID: 22156658
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current state of vaccine therapies in non-small-cell lung cancer.
    Romero P
    Clin Lung Cancer; 2008 Feb; 9 Suppl 1():S28-36. PubMed ID: 18540532
    [TBL] [Abstract][Full Text] [Related]  

  • 12. What lies within: novel strategies in immunotherapy for non-small cell lung cancer.
    Forde PM; Reiss KA; Zeidan AM; Brahmer JR
    Oncologist; 2013; 18(11):1203-13. PubMed ID: 24105749
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vaccines for the treatment of non-small cell lung cancer: investigational approaches and clinical experience.
    Mellstedt H; Vansteenkiste J; Thatcher N
    Lung Cancer; 2011 Jul; 73(1):11-7. PubMed ID: 21474197
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune modulations during chemoimmunotherapy & novel vaccine strategies--in metastatic melanoma and non small-cell lung cancer.
    Iversen TZ
    Dan Med J; 2013 Dec; 60(12):B4774. PubMed ID: 24355457
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immune Responses to the Cancer Testis Antigen XAGE-1b in Non Small Cell Lung Cancer Caucasian Patients.
    Saito K; Nakayama E; Valmori D
    PLoS One; 2016; 11(3):e0150623. PubMed ID: 26937656
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vaccines for the treatment of non-small cell lung cancer: a renewed anticancer strategy.
    Gridelli C; Rossi A; Maione P; Ferrara ML; Castaldo V; Sacco PC
    Oncologist; 2009 Sep; 14(9):909-20. PubMed ID: 19726457
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Belagenpumatucel-L for the treatment of non-small cell lung cancer.
    Rijavec E; Biello F; Genova C; Barletta G; Maggioni C; Dal Bello MG; Coco S; Truini A; Vanni I; Alama A; Beltramini S; Grassi MA; Boccardo F; Grossi F
    Expert Opin Biol Ther; 2015; 15(9):1371-9. PubMed ID: 26211534
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cancer immunotherapy: a future paradigm shift in the treatment of non-small cell lung cancer.
    Anagnostou VK; Brahmer JR
    Clin Cancer Res; 2015 Mar; 21(5):976-84. PubMed ID: 25733707
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunotherapy for non-small cell lung cancer: novel approaches to improve patient outcome.
    Shepherd FA; Douillard JY; Blumenschein GR
    J Thorac Oncol; 2011 Oct; 6(10):1763-73. PubMed ID: 21876456
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Beyond the standard of care: a review of novel immunotherapy trials for the treatment of lung cancer.
    Hall RD; Gray JE; Chiappori AA
    Cancer Control; 2013 Jan; 20(1):22-31. PubMed ID: 23302904
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.